Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Gracell Biotechnologies Inc. (GRCL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.9900-0.4200 (-7.76%)
At close: 04:00PM EDT
4.9200 -0.07 (-1.40%)
After hours: 06:53PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.4100
Open5.4200
Bid4.7700 x 1100
Ask5.2100 x 3100
Day's Range4.8500 - 5.4331
52 Week Range1.6800 - 15.0000
Volume121,481
Avg. Volume156,166
Market Cap336.822M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.2430
Earnings DateAug 17, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.25
  • PR Newswire

    Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences

    Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one meetings at three investor conferences in June 2022 as follows:

  • Benzinga

    Gracell Reveals Encouraging Data From Pretreated Multiple Myeloma Patients

    Gracell Biotechnologies Inc (NASDAQ: GRCL) announced the updated clinical data on GC012F, an autologous CAR-T therapeutic candidate dual-targeting B-cell maturation antigen (BCMA) and CD19, for relapsed/refractory multiple myeloma (RRMM). From October 2019 to January 2022, 29 heavily pretreated patients were enrolled and treated with a single infusion of GC012F at three dose levels (DL). At the data cutoff of June 8, 2022, the response rate at different dose levels was 100% (2/2) in DL1, 80% (8/

  • PR Newswire

    Gracell Biotechnologies Presents Updated Clinical Data for BCMA/CD19 Dual-targeting FasTCAR GC012F in RRMM at EHA2022 Congress, Highlighting 100% MRD Negativity Rate in All Treated Patients

    Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the updated clinical data from a multicenter study evaluating GC012F, the Company's autologous CAR-T therapeutic candidate dual-targeting B-cell maturation antigen (BCMA) and CD19, for the treatment of relapsed/refractory multiple myeloma (RRMM). Gracell shar

Advertisement
Advertisement